April 3, 2013
EPA Approves Apivar
Honeybee Miticide For Use
In All 50 United States
Varroa mite infestation in honeybee colonies; Apivar® is a factor in stemming
U.S. honeybee colony decline.
New York, NY –April 2, 2013 –Véto-pharma S.A., the French veterinary
pharmaceutical company specializing in honeybee health, announced today that
the U. S. Environmental Protection Agency (EPA) granted Section 3 registration
approval of its Apivar® miticide effective March 11, 2013. EPA approval means
that beekeepers anywhere in the U.S. will soon be allowed to use Apivar to treat
honeybee colonies for Varroa mites, one of the leading causes of global
honeybee population decline and a contributing factor in Colony Collapse
Disorder (CCD). Véto-pharma is submitting approval applications for individual
states and anticipates this process will be complete by the end of April.
"Apivar has earned an excellent reputation as a safe and effective means of
controlling Varroa mite infestations in honeybee colonies," says José Nobre,
Véto-pharma's president and chief executive officer. "Now American
beekeepers can take advantage of the same benefits that much of the rest of
the world has enjoyed for some time: Apivar kills up to 99 percent of Varroa
mites in one application; it has proven safe and effective for more than 15
years; it leaves no significant residues in hive products; and, it is convenient
and easy to use."
Varroa mites damage honeybees by feeding off their haemolymph (blood),
particularly at the larval stage, where they weaken the host bees and introduce
other diseases, viruses and bacteria. If left untreated, or without appropriate
control of the Varroa mite infestation, colonies are subject to a high risk of
death and become more susceptible to CCD. As a result, Varroa mites are
recognized as the biggest challenge facing the beekeeping industry worldwide.
Several research projects conducted by scientists in the U.S., Canada, and
many European and Asian nations have demonstrated Apivar's safety and
effectiveness when used in accordance with instructions. Similarly, other
studies have proven that residues of Apivar's active ingredient in honey and
wax consistently fall below the limits of detection, and are well below the strict
limits allowed by many regulatory bodies, notably the U.S. EPA and the
European Medicines Agency.
Apivar's long-acting, low-dose formulation means that when beekeepers
handle and apply the product as directed, they can be confident they will not be
exposed to any hazardous compounds. Apivar does not emit vapors into the
beehive atmosphere or the surrounding environment during application, nor
does it require measuring, mixing or any complicated application procedures.
"Canada’s regulatory agency granted full approval to Apivar in July 2012, so,
now that the U.S. is on board, we are very enthusiastic about the impact that
Apivar can have on the health of the North American honeybee population,"
Nobre said. "Early indications tell us the product is being warmly welcomed in
the U.S. market, and we look forward to moving Apivar into the Mexican
market in the very near future."
Véto-pharma S.A. is a veterinary pharmaceutical company that develops and
markets innovative products to help commercial and hobbyist beekeepers
prevent and control hive diseases and improve honeybee health. Véto-pharma's
products are sold to beekeepers through distributors in North America, Europe
and Asia. Headquartered in Paris, the Company's U.S. operations are based in
New York, NY. Visit www.apivar.net for more information.
Click here to see a digital sample of the American Bee Journal.
To subscribe to the American Bee Journal click here and
choose digital or the printed version.
For a calendar of scheduled beekeeping short courses and meetings, check our Events section of our website: http://www.americanbeejournal.com/site/epage/79331_828.htm
Check out Dadant & Sons, Inc. Website. Click here.
Brought to you by the American Bee Journal, the Beekeeper's Companion since 1861
Check out our website at www.americanbeejournal.com